Potent Reversible Inhibitors of the Protein Tyrosine Phosphatase CD45

Citations Over TimeTop 18% of 2001 papers

Abstract

The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated hematopoietic cells, contains protein tyrosine phosphatase activity and is critical for T-cell receptor-mediated T-cell activation. CD45 inhibitors could have utility in the treatment of autoimmune disorders and organ graft rejection. A number of 9,10-phenanthrenediones were identified that reversibly inhibited CD45-mediated p-nitrophenyl phosphate (pNPP) hydrolysis. Chemistry efforts around the 9,10-phenanthrenedione core led to the most potent inhibitors known to date. In a functional assay, the compounds were also potent inhibitors of T-cell receptor-mediated proliferation, with activities in the low micromolar range paralleling their enzyme inhibition. It was also discovered that the nature of modification to the phenanthrenedione pharmacophore could affect selectivity for CD45 over PTP1B (protein tyrosine phosphatase 1B) or vice versa.

Related Papers

• → Receptor-type protein tyrosine phosphatases in cancer(2014)82 cited
• → Protein Tyrosine Phosphatases: Mechanisms in Cancer(2021)54 cited
• → Tuning the Protein Phosphorylation by Receptor Type Protein Tyrosine Phosphatase Epsilon (PTPRE) in Normal and Cancer Cells(2018)19 cited
• → The regulation of B- and T-lymphocyte activation by the transmembrane protein tyrosine phosphatase CD45(1994)40 cited
• → Mutations in Tyrosine Kinase and Tyrosine Phosphatase and their Relevance to the Target Therapy in Hematologic Malignancies(2015)9 cited